Navidea Biopharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference
- Dr. Mark Pykett to Provide Business and Development Program Update -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, President and CEO, will participate at the Credit Suisse 2012 Healthcare Conference from November 14-16, 2012 at the Arizona Biltmore Hotel in Phoenix, Arizona. Dr. Pykett will provide an update of the Company and its development programs on Wednesday, November 14, 2012 at 7:30 AM Mountain Time (9:30 AM ET).
Investors and the public are invited to listen to a live webcast of Dr. Pykett's presentation at http://cc.talkpoint.com/cred001/111412a_am/?entity=63_2JP3N7R. Following the conference, a webcast will be archived for approximately 30 days.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, NAV5001 (CFT) and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Brent Larson, 614-822-2330
Sr. VP & CFO
KEYWORDS: United States North America Arizona Ohio
The article Navidea Biopharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.